The goal of this clinical trial is to analyse efficacy and safety of ixekizumab in participants with refractory guttate psoriasis. The main question it aims to answer is:
What percentage of participants achieved more than 90% reduction from baseline in Psoriasis Area Index （PASI 90） after 12 weeks of ixekizumab treatment? Participants will receive a 12-week treatment of ixekizumab, with follow-up visits every 2 weeks during the treatment period. Keep a diary of their symptoms and Psoriasis Area Index.

开始日期2025-05-01

申办/合作机构

浙江大学医学院附属第二医院（浙江省第二医院）

NCT06786936

/ Not yet recruitingN/AIIT

Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms

The investigators seek clinically actionable understanding of the mechanisms that underlie depression in the context of immune mediated inflammatory diseases (IMIDs), delivered by a focused immune intervention study examining brain circuitry using state of the art imaging in the context of exquisitely specific therapeutic immune interception in human immune disease.
Glutamate concentration in the NAcc will be positively correlated with the magnitude of the inflammatory response and will be attenuated by IL-17A inhibition. Ultimately, this will be associated with an improvement in depressive symptoms.
The strength of coupling between early and late systems will be attenuated in the context of IL-17A-driven inflammation and will be correlated with less frequent switching behaviour following negative outcomes and ultimately depressive symptoms. This coupling will be re-established following IL-17 antagonism.
Patients whose depressive symptoms benefit most from IL-17A antagonism will exhibit greatest resting-state and task-specific functional connectivity between Th-NAcc.

开始日期2025-02-28

申办/合作机构

NHS Greater Glasgow & Clyde

[+2]

NCT05309616

/ Recruiting临床2期IIT

Effects of IL-17A Inhibition on Idiopathic Subglottic Stenosis

The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.

开始日期2025-02-20

申办/合作机构

Yale University

100 项与依奇珠单抗相关的临床结果

登录后查看更多信息

100 项与依奇珠单抗相关的转化医学

登录后查看更多信息

100 项与依奇珠单抗相关的专利（医药）

登录后查看更多信息

1,104

项与依奇珠单抗相关的文献（医药）

2025-05-23·CLINICAL AND EXPERIMENTAL DERMATOLOGY

Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China

Article

作者: Lv, Chengzhi ; Liu, Yizhang ; Duan, Yongfang ; Zhang, Mi ; Hu, Kun ; Jian, Lu ; Sha, Yang ; Kuang, Yehong

Abstract:

Background:

New interleukin (IL)-17A inhibitors seem to demonstrate smaller effects on tuberculosis (TB) reactivation than expected.

Objectives:

To evaluate the risk of TB reactivation, to assess serial interferon (IFN)-γ levels, and to weigh up the risks and benefits of TB chemoprophylaxis in patients with psoriasis treated with IL-17A inhibitors.

Methods:

This dual-centre study included patients with psoriasis who were treated with IL-17A inhibitors. The incidence of active TB, serial IFN-γ levels tested by IFN-γ release assays (IGRAs), adverse events (AEs) and effectiveness were evaluated through 1 year in patients with psoriasis treated with IL-17A inhibitors. According to the chemoprophylaxis treatment regimen, patients with latent TB infection (LTBI) were classified into three groups: a complete chemoprophylaxis dose regimen (CCP), an incomplete chemoprophylaxis (ICCP) or no chemoprophylaxis (NCP).

Results:

In 220 IGRA-negative patients, 17 of 220 (7.3%) became IGRA positive after receiving a mean of 69.1 weeks of IL-17A inhibitor treatment. Only one case of new-onset TB was observed after 52 weeks of ixekizumab therapy. Significant changes in IFN-γ levels were observed in IGRA-negative patients. Similarly, IFN-γ levels [listed as the mean (SD)] significantly increased at 1 year compared with baseline among IGRA-positive patients in the NCP [105 (68.7) vs. 236 (80.8) pg mL−1, P < 0.01] and ICCP [75.3 (48.3) vs. 608 (249) pg mL−1, P < 0.001] groups, whereas the changes were not significant [125 (26.6) vs. 131 (21.7) pg mL−1, P = 0.70] in the CCP group.

Conclusions:

During IL-17A inhibitor therapy, there is a need for increased awareness of annual screening and assessment of individual risk for early detection of TB infection. LTBI treatment is generally well tolerated and is effective in preventing increased IFN-γ responses in patients with psoriasis treated with IL-17A inhibitors.

2025-05-19·POSTGRADUATE MEDICINE

Unveiling the effectiveness and safety spectrum of biologic therapies in psoriasis: a three-year real-world analysis

Article

作者: Diremsizoglu, Esin ; Demirbas, Abdullah ; Esen, Mustafa ; Ulutas Demirbas, Gozde

BACKGROUND:

Psoriasis vulgaris is a chronic immune-mediated inflammatory disease that significantly affects quality of life, particularly in severe cases and anatomically challenging areas. Biologic therapies targeting immune pathways have improved clinical outcomes; however, variability in effectiveness, safety, and drug survival necessitates further investigation.

OBJECTIVES:

This study aimed to evaluate the effectiveness, safety, and drug survival of biologic therapies in patients with moderate-to-severe psoriasis vulgaris.

METHODS:

A retrospective cohort study was conducted on 400 psoriasis patients treated with IL-17, IL-12/23, and IL-23 inhibitors. Clinical outcomes were assessed using PASI, DLQI, PSSI, NAPSI, and ppPASI scores. Kaplan-Meier survival analysis and Cox regression were employed to identify predictors of drug survival.

RESULTS:

Ixekizumab demonstrated superior effectiveness in achieving PASI 100 and improving scalp psoriasis, while Guselkumab provided the most sustained improvements in palmoplantar and nail involvement. Adverse events were most frequently associated with IL-17 inhibitors, particularly upper respiratory tract infections. Guselkumab and Secukinumab demonstrated the highest drug survival rates, whereas Ixekizumab had the lowest. Early improvements in PASI and DLQI scores were strong predictors of drug survival.

CONCLUSION:

Personalized treatment approaches are crucial, given the varied effectiveness, safety profiles, and drug survival among biologic therapies.

2025-05-01·EXPERIMENTAL DERMATOLOGY

Extension of Secukinumab and Ixekizumab Dose for Moderate‐To‐Severe Psoriasis in Low Disease Activity Intervals

Article

作者: Ning, Jiao ; Zhou, Jian ; Wang, Ziyuan ; Wang, Gang ; Yang, Yang ; Liu, Yanhua ; Liu, Xiaoming ; Jian, Ping ; Xing, Xiaoyi ; Xu, Zhongrui ; Wang, Caiyu ; Xu, Guangquan ; Yu, Chen

ABSTRACT:

Biological agents targeting IL‐17A, such as secukinumab and ixekizumab, are highly effective in treating psoriasis, often achieving low disease activity or remission. However, frequent injections, side effects and high costs pose significant challenges. Extending dosing intervals for patients with stable disease and partial response may address these issues while maintaining efficacy, yet standardised dose reduction guidelines remain absent. This study aimed to evaluate the efficacy and safety of reduced dosing regimens of secukinumab and ixekizumab during the maintenance phase of psoriasis treatment. From 2020 to 2023, patients completing induction and maintenance phases with prescribed regimens, achieving a PASI (Psoriasis Area and Severity Index) score below 1 and PASI90 or PASI100 response, underwent clinician evaluations for extended dosing intervals. Secukinumab dosing was adjusted from 300 mg (or 150 mg) Q4W to Q8W, and ixekizumab from 80 mg Q4W to Q8W. Patients were monitored over 36 weeks, with data collected throughout the observation period to assess feasibility and safety. A total of 64 patients with moderate‐to‐severe plaque psoriasis were enrolled. Following extended dosing intervals, 75.4% maintained a PASI90 response at 12 weeks, with 67.7% sustaining it at 36 weeks. Similarly, 69.8% achieved PASI100 at 12 weeks, and 61.2% maintained this response at 36 weeks. These findings demonstrate that dose reduction strategies for secukinumab and ixekizumab in moderate‐to‐severe psoriasis can reduce treatment burden while maintaining high therapeutic efficacy, offering valuable insights to guide clinical guidelines and address current knowledge gaps.

277

项与依奇珠单抗相关的新闻（医药）

2025-05-21

·PipelineReview

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant improvement over standard of care MENLO PARK, CA, USA I May 20, 2025 I Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-002, the Company’s novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-17A and IL-17F (IL-17A/F). “With both ORKA-001 and ORKA-002 now in human trials, we are moving quickly to demonstrate the clinical differentiation of both assets,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka. “Bimekizumab is launching extremely well as IL-17A/F has emerged as superior to IL-17A inhibition in several important indications. Uniquely, we could have the best targeting approaches for both IL-23p19 and IL-17A/F, potentially allowing us to offer the ideal regimen to patients through our ORKA-001 and -002 monotherapies and our ORKA-021 sequential combination.” The ORKA-002 Phase 1 trial is a double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability and pharmacokinetics (PK) of ORKA-002 in approximately 24 healthy volunteers across three subcutaneous dose cohorts. Oruka expects to share interim data from this study around year end 2025. Pending data from the Phase 1 trial, Oruka plans to initiate a Phase 2 study of ORKA-002 in moderate-to-severe psoriasis in the first half of 2026. The planned study design will evaluate the safety and efficacy of multiple dose levels and regimens of ORKA-002, with a primary endpoint of PASI 100 at week 16. “ORKA-002 has the opportunity to become the best antibody in the IL-17 class, which is preferred when treating psoriasis with joint involvement or recalcitrant skin disease, as well as psoriatic arthritis, hidradenitis suppurativa, and beyond,” said Joana Goncalves, MBChB, Chief Medical Officer of Oruka. “With this program now in the clinic, we are one step closer to our goal of offering the most possible freedom from disease to patients with psoriasis and other conditions.” About ORKA-002 ORKA-002 is a novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-17A/F. Dual inhibition of both IL-17A and IL-17F has shown superior efficacy compared to IL-17A inhibition alone in psoriasis (PsO) and other indications, as shown by the performance of Bimzelx (bimekizumab) compared to Cosentyx (secukinumab) and Taltz (ixekizumab) in Phase 3 trials. These therapies all utilize monthly maintenance dosing in PsO and psoriatic arthritis (PsA), except Bimzelx in PsO patients weighing <120 kg, where Q8W maintenance dosing is recommended. In contrast, ORKA-002 has the potential to be dosed just two to three times per year in PsO and PsA, which we believe could allow ORKA-002 to become the leading therapy in the IL-17 class. Data from studies in non-human primates and other preclinical assays show that ORKA-002 binds to a similar epitope with similar affinity as bimekizumab and has a significantly extended half-life over three times longer than bimekizumab. About Oruka Therapeutics Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn. SOURCE: Oruka Therapeutics

临床1期临床3期临床结果

2025-05-21

·PipelineReview

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

HENDERSON, NV, USA I May 20, 2025 I Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases with unmet needs, today announced the launch of TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe HS. “Hidradenitis suppurativa remains a difficult condition to manage, with many patients experiencing persistent disease activity despite currently available treatments,” said Alexa B. Kimball, MD, MPH, Professor of Dermatology at Harvard Medical School, and President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center. “Studying tibulizumab represents an important opportunity to evaluate an investigational therapy designed to target multiple aspects of the inflammatory process in HS. We look forward to investigating this approach for individuals living with this challenging disease.” TibuSHIELD is designed to enroll approximately 180 adults with moderate to severe HS across the United States, Canada, and Europe. The study will evaluate tibulizumab over a 28-week period, comprising a 16-week primary efficacy assessment and a 12-week safety follow-up, with an optional OLE. Topline results for the primary efficacy endpoint at Week 16 are expected in the third quarter of 2026. “The initiation of TibuSHIELD marks a key milestone in our mission to advance potentially differentiated therapies for patients with severe inflammatory diseases, ” said Kiran Nistala, MBBS, PhD, Chief Medical Officer and Head of Development at Zura Bio. “Tibulizumab’s dual mechanism of action, targeting both BAFF and IL-17A, offers a novel approach for the potential treatment of hidradenitis suppurativa. We remain committed to advancing clinical development with investigators, clinical sites, and the HS community.” The launch of this HS study follows the December 2024 initiation of TibuSURE, a global Phase 2 study evaluating tibulizumab in adults with systemic sclerosis. Tibulizumab remains an investigational product and has not been approved by any regulatory authority. Its safety and efficacy have not yet been established. ABOUT TibuSHIELD TibuSHIELD is a global, Phase 2, randomized, double-blind, placebo-controlled clinical study evaluating the safety, tolerability, and efficacy of tibulizumab in approximately 180 adults with moderate to severe HS. Participants are randomized 1:1:1 to receive two different doses of tibulizumab or placebo. The study includes a 16-week efficacy assessment period followed by a 12-week safety follow-up and an optional OLE. The primary endpoint of the study is the percent change from baseline in total abscess and nodule (AN) count at Week 16. Secondary endpoints include the proportion of participants achieving HiSCR50 or HiSCR75, defined as at least a 50% or 75% reduction in AN count without an increase in abscesses or draining fistulas at Week 16. Key safety assessments include the assessment of tolerability, and monitoring for adverse events. ABOUT HIDRADENITIS SUPPURATIVA Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, progressive, and debilitating inflammatory skin disease affecting approximately 1% of the global population. HS primarily involves follicular occlusion, rupture, and secondary inflammation of hair follicles, leading to painful nodules, abscesses, sinus tracts (also referred to as draining tunnels), and scarring. Lesions typically occur in areas where skin rubs together, such as the armpits, groin, and under the breasts. HS is associated with several comorbidities, including inflammatory arthropathies, metabolic syndrome, increased cardiovascular risk, inflammatory disorders, lymphedema, squamous cell carcinoma, and depression. The chronic pain, visible scarring, and disease burden contribute significantly to physical disability, stigmatization, unemployment, and reduced quality of life. Currently, there is no cure for HS. Despite its relatively high prevalence and disease burden, treatment options remain limited, and many patients fail to achieve adequate disease control. ABOUT TIBULIZUMAB Tibulizumab is an investigational, humanized, tetravalent dual-antagonist antibody engineered by fusing Taltz® (ixekizumab) and tabalumab to bind to and neutralize both IL-17A and BAFF. It is currently being evaluated in two Phase 2 clinical studies in adults with systemic sclerosis and hidradenitis suppurativa. Prior to in-licensing, Phase 1/1b studies were conducted in patients with Sjögren’s syndrome and rheumatoid arthritis. Tibulizumab is an investigational compound and has not been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. ABOUT ZURA BIO Zura Bio is a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases with unmet needs. The Company’s pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura Bio’s lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies in adults, including TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. Additional product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. For more information, please visit www.zurabio.com . SOURCE: Zura Bio

临床2期免疫疗法

2025-05-14

·摩熵医药

自免药物黄金赛道争夺：IL抑制剂4大靶点解析，中国药企逆袭罗氏、诺华…

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。在全球自身免疫疾病患病人群突破4亿的背景下，其治疗手段也日益丰富。白细胞介素（IL）抑制剂作为一类重要的生物制剂，正逐步成为治疗多种自身免疫性疾病的一线选择。摩熵咨询最新发布的《自免药物（IL抑制剂篇）市场研究专题报告》深入剖析了IL抑制剂的作用机制、上市药物情况以及市场竞争格局，为药企研发、临床用药选择及市场投资决策提供了极具价值的参考依据。以下内容将基于该报告的精选部分，聚焦于IL抑制剂的作用机制及上市药物情况，揭示其在自身免疫疾病治疗中的重要地位。 01IL抑制剂作用机制及上市代表药物 01IL-4：特应性皮炎和哮喘的强势靶点白细胞介素-4（IL-4）是一种糖基化的Ⅰ型细胞因子，主要由T细胞、自然杀伤T细胞、肥大细胞和嗜酸性粒细胞产生。IL-4只有与位于靶细胞膜上的特异性受体结合才能发挥其生物学活性。常见的白细胞介素4受体（IL-4R）有2种类型：Ⅰ型受体主要位于T细胞和自然杀伤细胞（naturalkillercell，NK）表面，由IL-4Rα亚基和γc亚基组成；Ⅱ型受体常见于各种实体瘤表面，由IL-4Rα亚基和白细胞介素13受体α1（IL-13Rα1）亚基组成。IL-4在免疫系统中发挥重要作用，IL-4参与免疫细胞的存活、发育。IL-4控制B细胞存活、发育和成熟以及Ⅱ型辅助性T细胞的增殖分化；IL-4还可以将巨噬细胞诱导转变为活化的形式。上市药物与研发进展：全球标杆：赛诺菲/再生元的度普利尤单抗（Dupilumab）是全球首款获批的IL-4抗体药物，通过阻断IL-4/IL-13信号，覆盖特应性皮炎、哮喘等适应症，2020年销售额超40亿美元。中国突破：石药集团/康诺亚生物的司普奇拜单抗（CM310）作为国内首个、全球范围第二个获批上市的IL-4Rα抗体药物，填补了国产特应性皮炎生物制剂领域的空白。据摩熵医药数据库统计，截至2024年12月，目前国内有8款在研IL-4R单抗处于III期临床阶段，包括SHR-1819（恒瑞医药）、GR-1802（智翔医药）、SSGJ-611（三生制药）、Comekibart（麦济生物）、Rademikibart（康乃德/先声药业）、QX-005-N（荃信生物）和Manfidokimab（康方生物）、TQH-2722（正大天晴）。数据来源：摩熵医药数据库02IL-6通路：双重信号传导机制与炎症调控IL-6的作用由经典信号传导和反式信号传导两种机制引起。白细胞介素-6（IL-6）是一种B细胞刺激因子，可以促进效应B细胞向产生抗体的细胞分化。单核细胞和巨噬细胞是IL-6的主要产生细胞，T细胞、B细胞经刺激也可以产生IL-6。IL-6在类风湿关节炎等慢性炎症中起关键作用。IL-6结合受体有两种，一种是特异性受体IL-6R（80kDaI型跨膜蛋白），另一种是gp130，是IL-6家族细胞因子的所有成员的常见受体亚单位。gp130可以在所有细胞表达，但IL-6R的表达受到更多的限制，主要发现于肝细胞、嗜中性粒细胞、单核细胞和CD4+T细胞。IL-6和IL-6Rα结合，形成与gp130同型二聚体缔合的复合物，形成2个配体分子的六聚体复合物，2个α亚基分子和2个gp130分子（经典信号传导）。sIL-6Rα无需膜结合的IL-6Rα即可激活gp130信号传导，使缺乏膜结合的IL-6Rα的细胞能够对IL-6作出反应（反式信号转导）。上市药物与研发进展：全球首秀：罗氏的托珠单抗（Tocilizumab）是首个上市的IL-6靶向药物，是类风湿关节炎一线生物制剂，获《2024中国类风湿关节炎诊疗指南》推荐。中国挑战：国内IL-6靶向药物研发相对滞后，本土创新管线较少。图片来源：摩熵咨询《自免药物（IL抑制剂篇）市场研究专题报告》03IL-17：银屑病与脊柱炎的攻坚靶点白细胞介素-17（IL-17）细胞因子家族由六个成员组成，IL-17/IL-17A、IL-17B、IL-17C、IL-17D、IL-17E/IL-25和IL-17F，它们由许多不同类型的细胞产生，主要促进促炎免疫反应。IL-17A和IL-17F是IL-17研究最广泛的两种因子，IL-17A和IL-17F的同源性最高，主要由Th17细胞分泌。IL-17A的信号转导调节主要依赖于TRAF6、Act1、microRNA-23b等重要分子。在IL-17A高表达的自身免疫疾病如风湿性关节炎中，miR-23b的表达下降,解除了对IL-17-NF-κB的抑制,使得IL-17A信号过度活化而对炎症性疾病及自身免疫性疾病等起促进作用。上市药物与研发进展：全球领跑：诺华的司库奇尤单抗（Secukinumab）为全球首款IL-17A抑制剂，适应症覆盖银屑病关节炎、寻常型银屑病、斑块状银屑病、强直性脊柱炎、脓疱性银屑病等。中国爆发：截至2024年12月，国内已上市6款IL-17抗体药物，包含四款进口产品，分别是诺华的司库奇尤单抗，礼来的依奇珠单抗、协和麒麟的布罗利尤单抗，以及优时比的比奇珠单抗；以及两款国产新药，智翔金泰的赛立奇单抗、恒瑞医药的夫那奇珠单抗。此外，还有10余家企业紧追不舍，包括康方生物、三生国健、丽珠集团、华海药业、君实生物等多家药企的IL-17A单抗都处于临床3期阶段。04IL-12/IL-23：Th1与Th17通路的双重调控者白细胞介素-12（IL-12）与白细胞介素-23（IL-23）由活化的树突状细胞与巨噬细胞分泌，是具前炎症反应活性的细胞因子。其中IL-12可以刺激原始T细胞分化为Th1细胞，开启Th1型炎症反应，分泌IFN-γ与TNF等促炎因子；IL-23能够促进Th17细胞的存活和扩增，产生IL-17A、IL-17F、IL-22等促炎因子，引发特定部位的炎症反应。上市药物与研发进展：全球标杆：强生的乌司奴单抗（Ustekinumab）为全球首个可同时选择性靶向IL-12和IL-23的生物制剂，是银屑病和免疫疾病领域的“初代生物制剂王者”，其适应症扩展已至克罗恩病、溃疡性结肠炎。中国冲刺：截至2024年12月，康方生物AK101、信达生物IBI112两款国产药物已进入上市申请阶段，乌司奴单抗生物类似药紧随其后。02指南共识推动IL抑制剂临床地位升级多部自身免疫系统疾病指南已将白细胞介素抑制剂列为一线治疗选择。例如，《2024中国类风湿关节炎诊疗指南》明确指出了托珠单抗在治疗类风湿关节炎中的疗效和安全性；《中国银屑病生物制剂及小分子药物治疗指南（2024）》则推荐了IL-17A抑制剂、IL-12/23抑制剂等多种IL抑制剂作为治疗斑块状银屑病和关节病型银屑病的优选药物。这些指南的发布进一步巩固了IL抑制剂在自身免疫性疾病治疗中的地位。小结IL抑制剂作为自身免疫疾病治疗领域的重要创新药物，凭借其明确的作用机制和良好的临床疗效，正在改变相关疾病的治疗格局。摩熵咨询的报告不仅为行业厘清了技术路线与市场脉络，更预示了中国药企在IL-4R、IL-17等赛道的突围机遇。随着国产药物的密集上市与适应症拓展，IL抑制剂有望在全球千亿市场中占据更核心地位，为患者提供更优治疗选择。END本文为原创文章，转载请留言获取授权自免药物（IL抑制剂篇）市场研究专题报告下期内容预告目录一、93亿市场！IL抑制剂赛道，司库奇尤单抗狂揽41亿，恒瑞、石药紧追近期将持续更新，敬请期待近期热门资源获取数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况-2025042023H2-2024H1中国药品分析报告-2025042024年中国1类新药靶点白皮书-202503中国AI医疗健康企业创新发展百强榜单-202502解码护肤抗衰：消费偏好洞察与市场格局分析-2025022024年FDA批准上市的新药分析报告-2025012024年NMPA批准上市的新药分析报告-2025012024年医保谈判及市场分析报告-2025.012024年中国医疗健康投融资全景洞察报告-202501小分子化药白皮书（上）-2025012024医美注射材料市场发展分析报告-202412中国放射性药物产业白皮书-202410近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

临床3期上市批准临床2期

100 项与依奇珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10071	依奇珠单抗	L04AC13	DB11569

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
中轴性脊柱关节炎	中国	Eli Lilly & Co.	2022-07-26
强直性脊柱炎	加拿大	Eli Lilly & Co.	2016-08-11
非放射性轴性脊柱关节炎	加拿大	Eli Lilly & Co.	2016-08-11
脊椎关节炎	加拿大	Eli Lilly & Co.	2016-08-11
红皮病性银屑病	日本	Eli Lilly Japan KK	2016-07-04
银屑病	日本	Eli Lilly Japan KK	2016-07-04
寻常性银屑病	日本	Eli Lilly Japan KK	2016-07-04
脓疱型银屑病	日本	Eli Lilly Japan KK	2016-07-04
银屑病关节炎	欧盟	Eli Lilly & Company (Ireland) Ltd.	2016-04-25
银屑病关节炎	冰岛	Eli Lilly & Company (Ireland) Ltd.	2016-04-25
银屑病关节炎	列支敦士登	Eli Lilly & Company (Ireland) Ltd.	2016-04-25
银屑病关节炎	挪威	Eli Lilly & Company (Ireland) Ltd.	2016-04-25
斑块状银屑病	美国	Eli Lilly & Co.	2016-03-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖	临床3期	美国	Eli Lilly & Co.	2024-09-24
肥胖	临床3期	波多黎各	Eli Lilly & Co.	2024-09-24
附着点炎相关关节炎	临床3期	比利时	Eli Lilly & Co.	2021-04-13
附着点炎相关关节炎	临床3期	丹麦	Eli Lilly & Co.	2021-04-13
附着点炎相关关节炎	临床3期	德国	Eli Lilly & Co.	2021-04-13
附着点炎相关关节炎	临床3期	意大利	Eli Lilly & Co.	2021-04-13
附着点炎相关关节炎	临床3期	墨西哥	Eli Lilly & Co.	2021-04-13
附着点炎相关关节炎	临床3期	荷兰	Eli Lilly & Co.	2021-04-13
附着点炎相关关节炎	临床3期	西班牙	Eli Lilly & Co.	2021-04-13
附着点炎相关关节炎	临床3期	瑞士	Eli Lilly & Co.	2021-04-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04979910 (CTgov)	临床2期	重度抑郁症 \| 难治性抑郁症	7	Ixekizumab	艱觸顧觸鏇鑰淵餘網願 = 窪鑰遞夢構艱遞鏇繭憲窪襯淵繭糧簾餘選構醖 (願製築膚襯鏇獵顧鑰築, 鏇獵鹹醖壓遞膚觸鹽繭 ~ 鑰範膚範糧糧夢膚廠鑰) 更多	-	2025-05-20
NCT04285229 (Pubmed \| Rheumatol Ther)	临床3期	中轴性脊柱关节炎 C-reactive protein level	147	Ixekizumab 80 mg every 4 weeks	選廠願繭積顧鹹廠鹽壓(衊鏇製構鏇艱鑰襯積願) = 簾艱範網築範鹹觸糧觸鹽積築襯構積膚夢齋鹹 (構願憲衊醖糧憲膚醖鑰 )	积极	2025-05-09
				Placebo	選廠願繭積顧鹹廠鹽壓(衊鏇製構鏇艱鑰襯積願) = 齋選憲選壓製鹹範簾鹹鹽積築襯構積膚夢齋鹹 (構願憲衊醖糧憲膚醖鑰 )
NCT03364309 (Phase 3 Trial, Pubmed \| Adv Ther)	临床3期	银屑病	289	Ixekizumab	襯膚鹹顧艱構網製願齋(艱觸鑰窪構繭選壓顧築) = AEs were comparable in patients who received continuous treatment and retreatment 顧築網網製鹽簾衊鏇積 (醖範獵憲艱艱顧願憲糧 )	积极	2024-11-13
NCT02696785 (COAST-V, Pubmed) 人工标引	临床3期	中轴性脊柱关节炎 bDMARD-naïve \| r-axSpA	81	Ixekizumab 80 mg every 4 weeks	簾鬱鹹齋襯鏇艱範廠獵(積鏇遞鏇廠艱遞鹽糧鹹) = 顧鏇顧鏇鬱淵鹽簾願襯簾廠憲夢觸壓選壓鑰鏇 (鏇糧製鹽鹽獵醖觸糧構 ) 更多	积极	2024-07-01
NCT04527380 (COSPIRIT-JIA, EULAR 12024 \| EULAR 22024) 人工标引	临床3期	附着点炎相关关节炎 \| 幼年特发性关节炎	101	Ixekizumab (All IXE)	獵積顧壓網壓廠鹹醖蓋(築醖鑰築觸製網積壓積) = 鬱齋願鑰壓衊構醖鑰餘壓壓範鑰鬱簾獵願憲艱 (觸蓋範夢齋築廠齋積夢 ) 更多	积极	2024-06-12
				Ixekizumab (Bio-Naive)	獵積顧壓網壓廠鹹醖蓋(築醖鑰築觸製網積壓積) = 製淵顧鹽網齋廠夢廠窪壓壓範鑰鬱簾獵願憲艱 (觸蓋範夢齋築廠齋積夢 ) 更多
NCT02696785 (COAST-V, EULAR2024)	临床3期	中轴性脊柱关节炎	341	Ixekizumab Q4W	簾顧遞膚鬱膚鑰憲構淵(醖膚鏇顧獵鏇鹽築鏇膚) = 膚遞淵醖簾繭鏇鬱網蓋衊簾壓齋鑰鑰膚衊範築 (簾窪醖襯繭簾齋憲觸憲 ) 更多	积极	2024-06-05
				Ixekizumab Q2W	簾顧遞膚鬱膚鑰憲構淵(醖膚鏇顧獵鏇鹽築鏇膚) = 蓋憲願製積衊積鬱淵簾衊簾壓齋鑰鑰膚衊範築 (簾窪醖襯繭簾齋憲觸憲 ) 更多
EULAR2024	N/A	非放射性轴性脊柱关节炎	-	Ixekizumab 80 mg every 4 weeks	廠憲憲齋淵艱夢觸壓鏇(製鬱選鏇淵淵網窪廠糧) = 齋糧鏇鏇遞餘壓築網觸淵鹹獵網鑰鹽積獵觸鬱 (餘製壓觸衊窪網鹽範糧 ) 更多	-	2024-06-05
				Placebo	廠憲憲齋淵艱夢觸壓鏇(製鬱選鏇淵淵網窪廠糧) = 襯醖壓構鬱鏇構構夢觸淵鹹獵網鑰鹽積獵觸鬱 (餘製壓觸衊窪網鹽範糧 ) 更多
EULAR2024	N/A	银屑病关节炎 \| 中轴性脊柱关节炎 interleukin 17A (IL17A)	335	Ixekizumab	網構衊構艱夢鏇艱選衊(鹽範鹽網鬱糧積襯積糧) = 獵鏇壓範膚廠艱齋醖餘膚獵積積鬱壓壓簾鏇餘 (蓋範網淵餘網築築廠壓, 64.0 ~ 74.3)	积极	2024-06-05
EULAR2024	N/A	中轴性脊柱关节炎一线 HLA-B27	-	Ixekizumab	餘顧獵鑰獵齋簾構廠衊(鑰鏇憲簾觸鬱範膚遞鹽) = 餘餘遞鏇膚觸選選繭淵壓構遞壓憲觸顧憲鏇鹽 (蓋觸繭壓顧鹹獵憲鏇鬱 ) 更多	积极	2024-06-05
				Secukinumab	餘顧獵鑰獵齋簾構廠衊(鑰鏇憲簾觸鬱範膚遞鹽) = 積鬱鹹鑰遞範獵製鑰鹹壓構遞壓憲觸顧憲鏇鹽 (蓋觸繭壓顧鹹獵憲鏇鬱 ) 更多
EULAR2024	N/A	中轴性脊柱关节炎	-	Ixekizumab 80mg every 4 weeks	糧獵淵鏇選範蓋膚壓選(齋襯簾選網鹽網願艱築) = 壓願餘鹹遞齋鑰鏇築襯憲蓋醖積鏇醖衊廠憲獵 (網願廠膚築蓋繭鬱鹽糧 )	-	2024-06-05